Skip to content

Talphera, Inc. TLPH Other intangible assets—net

Other intangible assets—net at other companies

XOMA Corporation logo
XOMA CorporationXOMA
$43.86M+72.9%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$6.11M-90.9%
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$217.34M-15.9%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$174M-1.4%
Baxter International logo
Baxter InternationalBAX

Other financials

Income statement

See full
Revenue--100%
Gross profit-$1.9M-52.7%
Operating income-$3.9M-35.4%
Net income-$2.6M+1.4%
EPS (diluted)-$0.10+37.5%

Balance sheet

See full
Cash & equivalents$3.8M-29.0%
Total debt$3.4M-79.7%
Total equity$18.5M+230%
Total assets$30.2M+101%

Cash flow

See full
Operating cash flow-$3.4M+2.0%
CapEx-
Free cash flow-$2.3M+42.9%

Valuation

See full
Market cap$53.46M+516%
P/S53,456.6×+53,135×

Profitability

See full
Gross margin-127.7%-136pp
Operating margin-1,451,600%-1,507,145pp
Net margin-1,425,300%-1,471,200pp
FCF margin-5,116.7%-6,779pp

Returns & leverage

See full
Return on equity-118.4%+15.4pp
Debt / equity0.2×
Current ratio5.3×+2.2×

Where this comes from

Reported directly by Talphera, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IntangibleAssetsNetExcludingGoodwill.

The official record: Talphera, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Talphera, Inc.'s other intangible assets—net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Talphera, Inc.'s other intangible assets—net?
Talphera, Inc. (TLPH) reported other intangible assets—net of $8.82M in Q1 2026.
How has Talphera, Inc.'s other intangible assets—net changed year-over-year?
Talphera, Inc.'s other intangible assets—net decreased by 0.0% year-over-year, from $8.82M to $8.82M.
What does other intangible assets—net mean?
This represents the net book value of identifiable non-physical assets such as patents, intellectual property, software licenses, and trademarks, excluding goodwill. These assets are vital for companies relying on proprietary technology and R&D. It captures the value of the company's competitive moat derived from its intellectual property portfolio.